CRISPR Assays for Disease Diagnosis: Progress to and Barriers Remaining for Clinical Applications
Advanced Science · 2023-07 · 10 (20)
DOI: 10.1002/advs.202301697 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 10.05.2023. Verfasst von Zhen Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, 29 Bulan …. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Nucleic Acids. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Numerous groups have employed the special properties of CRISPR/Cas systems to develop platforms that have broad potential applications for sensitive and specific detection of nucleic acid (NA) targets. However, few of these approaches have progressed to commercial or clinical applications. This review summarizes the properties of known CRISPR/Cas systems and their applications, challenges associated with the development of such assays, and opportunities to improve their performance or address unmet assay needs using nano‐/micro‐technology platforms. These include rapid and efficient sample preparation, integrated single‐tube, amplification‐free, quantifiable, multiplex, and non‐NA assays. Finally, this review discusses the current outlook for such assays, including remaining barriers for clinical or point‐of‐care applications and their commercial development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, 29 Bulan Road, Shenzhen, Guangdong, 518112, China.
- Center for Cellular and Molecular Diagnostics, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA, 70112, USA.
- Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA, 70112, USA.
- Tolo Biotechnology Company Limited, 333 Guiping Road, Shanghai, 200233, China.
ORCID-Profile: Zhen Huang, Tony Y Hu
Förderung
- NIAID NIH HHS
- NIH HHS
- NCI NIH HHS
- NICHD NIH HHS
- NINDS NIH HHS
- National Institutes of Health
- U.S. Department of Defense
Zitieren
APA
Huang, Z., Lyon, C. J., Wang, J., Lu, S., & Hu, T. Y. (2023). CRISPR Assays for Disease Diagnosis: Progress to and Barriers Remaining for Clinical Applications. Advanced Science, 10(20). https://doi.org/10.1002/advs.202301697
Vancouver
Huang Z, Lyon CJ, Wang J, Lu S, Hu TY. CRISPR Assays for Disease Diagnosis: Progress to and Barriers Remaining for Clinical Applications. Advanced Science. 2023;10(20). doi:10.1002/advs.202301697
BibTeX
@article{Huang2023,
author = {Huang, Zhen and Lyon, Christopher J and Wang, Jin and Lu, Shuihua and Hu, Tony Y},
title = {CRISPR Assays for Disease Diagnosis: Progress to and Barriers Remaining for Clinical Applications},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {20},
doi = {10.1002/advs.202301697}
}
EUVIMED